Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acyclovir for HSV Suppression in HIV
NCT00001115Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Primary completion
- Jun 2005
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aciclovir in herpes simplex (HSV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Plasma HIV RNA levels at 3.5 months. Status: completed.
02
Drugs
aciclovir
03
Conditions
herpes simplex (HSV)
Beyond the preview
Go deeper on NCT00001115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001115.